Side-by-side · Research reference

CerebrolysinvsFOXO4-DRI

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED11/65 cited

BAnimal-StrongHUMAN-REVIEWED12/45 cited

Cerebrolysin

Porcine Brain-Derived Peptide Mix · Phase 3

30 mL/dayStandard doseAfridi 2026 Staszewski 2026

14–21 daysTreatment course

49% vs 35%mRS 0-2 at 12 moStaszewski 2026

IV infusion · 100-250 mL saline · Daily

FOXO4-DRI

Senolytic Peptide · D-Retro-Inverso

p53-TADMolecular targetBourgeois 2025

Pre-clinicalDevelopment stage

SQRoute (animal)

SQ · Animal models only

01Mechanism of Action

Parameter

Cerebrolysin

FOXO4-DRI

Primary target

Multiple neurotrophic pathways — mimics BDNF, NGF, CNTF receptor activation

FOXO4-p53 protein complex in senescent cellsBourgeois 2025 Tripathi 2021

Pathway

Cerebrolysin peptides → BDNF/NGF/CNTF receptor binding → TrkB/TrkA/LIFR signaling → neuroprotection, neuroplasticity, synaptogenesis

FOXO4-DRI binds disordered p53 transactivation domain → displaces FOXO4 → nuclear p53 exclusion → p53-mediated apoptosis in senescent cells

Downstream effect

Reduced apoptosis (Bax ↓, Bcl-2 ↑), suppressed TNF-α inflammation, elevated endogenous BDNF, enhanced synaptic plasticity and motor recovery

Selective apoptosis of senescent cells; clearance restores tissue homeostasisTripathi 2021 Alameen 2026

Feedback intact?

Yes — exogenous peptides do not suppress endogenous neurotrophic factor synthesis

—

Origin

Enzymatic breakdown of lipid-free porcine brain proteins → standardized low-MW peptide fraction (<10 kDa) + free amino acids

D-retro-inverso modification — inverted amino acid sequence, D-amino acids for protease resistance

Antibody development

Not reported in human trials; porcine origin theoretically immunogenic but no clinically significant allergic reactions documented

—

02Dosage Protocols

Parameter

Cerebrolysin

FOXO4-DRI

Standard dose (stroke)

30–50 mL / day IVStaszewski 2026 Afridi 2026

Most trials use 30 mL in 100-250 mL saline over 30-60 min.

—

Lower dose (dementia)

10–20 mL / day IV or IMKhatkova 2026

Chronic neurodegenerative conditions; intermittent courses.

—

High dose (TBI)

50 mL / day IVKobayashi 2025

CLINCH trial protocol for intracerebral hemorrhage.

—

Duration

10–21 days (acute); intermittent courses (chronic)

Stroke trials typically 10-14 days; rehabilitation phases may use repeated 10-day courses.

Weeks to months (animal studies)

Senescent cell clearance observed within weeks.

Timing (stroke)

Initiate within 12 hrs of symptom onset; up to 6 hrs optimal

Earlier initiation associated with better outcomes.

—

Adjunct to thrombectomy

30-50 mL daily × 10-14 days, starting day of EVT

Propensity-matched data show 12-mo mRS 0-2 improved from 35% to 49%.

—

Evidence basis

Phase 3 RCT + observational

Animal / mechanistic

Administration route

IV infusion (preferred) or IM injection

IV allows higher doses; IM used in outpatient/chronic settings.

—

Animal dose (mouse)

—

5 mg/kg

SQ injection, aged mouse model (testosterone restoration).

Frequency (animal)

—

Variable — single or intermittent dosing

Protocol-dependent; no standardised regimen.

Human equivalent (theoretical)

—

~0.4 mg/kg (28 mg / 70 kg adult)

Extrapolated using allometric scaling; no clinical validation.

Route

—

SQ (animal)

No human route established.

Clinical status

—

No human trials completed

04Side Effects & Safety

Parameter

Cerebrolysin

FOXO4-DRI

Injection site reaction

Mild pain, erythema (IM route)

—

Infusion reaction

Rare: flushing, transient hypotension during rapid IV

—

Agitation / Restlessness

Reported in <5% of patients; typically mild, self-limited

—

Headache

Mild, transient; incidence not significantly elevated vs placeboPatel 2025

—

Serious adverse events

No significant increase vs placebo (RR 1.02, 95% CI 0.87-1.20)

—

Hemorrhagic transformation

Reduced incidence vs control (52% reduction in high-risk post-thrombolysis cohort)Kalinin 2025

—

Mortality

No increase; meta-analysis RR 0.89 (0.68-1.18)

—

Allergic reaction

Rare; porcine origin theoretically immunogenic but clinically insignificant

—

Seizure risk

Not elevated; safe in epilepsy populations

—

Pulmonary hypertension risk

—

Senescent cell elimination promoted PH development/progression in rodent modelsBorn 2023

Context-dependent toxicity

—

Beneficial effects may be tissue/context-specific; elimination not universally protectiveBorn 2023

Off-target apoptosis

—

Theoretical risk of non-senescent cell apoptosis (selectivity not absolute)

Immune perturbation

—

Senescent cells contribute to immune surveillance; clearance effects unknown

Human safety unknown

—

No clinical trials — toxicity profile in humans not established

Absolute Contraindications

Cerebrolysin

·Known hypersensitivity to porcine-derived products
·Active seizure disorder (relative — caution advised)

FOXO4-DRI

·Pulmonary hypertension or vascular disease (preclinical evidence of harm)Born 2023
·Pregnancy / lactation (no safety data)

Relative Contraindications

Cerebrolysin

·Severe renal impairment (amino acid load — monitor)
·Pregnancy / lactation (insufficient safety data)

FOXO4-DRI

·Active malignancy (senescence as tumour suppressor mechanism)
·Wound healing / tissue repair (senescent cells involved in fibrosis resolution)

05Administration Protocol

Parameter

Cerebrolysin

FOXO4-DRI

1. Preparation (IV infusion)

Dilute prescribed dose (10-50 mL) in 100-250 mL 0.9% sodium chloride. Use immediately after preparation. Do not mix with other medications in same infusion bag.

Subcutaneous injection used in rodent models. No human administration protocol exists.

2. Infusion rate

Administer over 30-60 minutes. Slower infusion reduces risk of transient hypotension or flushing. Monitor vital signs during first administration.

Typically reconstituted in sterile saline or PBS for animal experiments. Stability data limited.

3. IM injection (alternative)

For 5-10 mL doses: inject deep IM into gluteal or deltoid muscle. Rotate sites if repeated daily. IM preferred for outpatient/chronic use.

Variable — single bolus or intermittent dosing over weeks. No standardised human protocol.

4. Timing

Acute stroke: initiate within 6-12 hrs of symptom onset. Daily administration, preferably same time each day. Continue 10-21 days per protocol.

No registered human trials. Commercialisation by Cleara Biotech (Netherlands) in development phase.

5. Storage

Store unopened ampoules at 15-25°C, protected from light. Do not freeze. Use diluted solution immediately; discard unused portion.

Would require cardiovascular assessment, pulmonary function, immune panel, tumour surveillance if human trials proceed.

6. Co-administration

Compatible with standard stroke care (thrombolysis, thrombectomy, antiplatelet/anticoagulant therapy). Does not interfere with reperfusion therapies.

—

06Stack Synergy

Cerebrolysin

+ Semax

Moderate

View Semax →

Cerebrolysin (multimodal neurotrophic peptide mix) and Semax (ACTH(4-10) analogue) operate through complementary neuroprotective pathways. Cerebrolysin elevates BDNF and suppresses apoptosis/inflammation via TrkB/TrkA signaling, while Semax enhances neuroplasticity through BDNF upregulation and dopaminergic modulation. Combined use in stroke or TBI may amplify anti-apoptotic effects and accelerate cognitive/motor recovery, though no direct RCT data exist for the combination.

Cerebrolysin: 30 mL IV daily × 10-14 days
Semax: 300-600 mcg intranasal BID × 10-14 days
Timing: Concurrent during acute recovery phase
Primary benefit: Enhanced neuroprotection, accelerated motor/cognitive recovery post-stroke or TBI

+ BPC-157

Multi-pathway

View BPC-157 →

Cerebrolysin provides CNS-specific neurotrophic support (BDNF, NGF pathways), while BPC-157 offers systemic tissue repair via angiogenesis (VEGF upregulation) and anti-inflammatory effects. In traumatic brain injury or stroke, Cerebrolysin addresses neuronal survival and synaptic plasticity, whereas BPC-157 may enhance vascular repair and blood-brain barrier integrity. The combination targets both neuronal and vascular compartments of brain injury, though clinical validation is lacking.

Cerebrolysin: 30-50 mL IV daily × 14 days
BPC-157: 250-500 mcg SQ daily × 14-28 days
Timing: Initiate both within 24-48 hrs of injury
Primary benefit: Dual neuronal + vascular repair in TBI or stroke; accelerated functional recovery

FOXO4-DRI

— no documented stacks